Skip to main content
SpringerLink
Log in

Mouse Models to Study Pro-and Antiangiogenic Potential: Novel Roles for PLGF and FLT1

  • Chapter
The Physiological Genomics of the Critically Ill Mouse

Part of the book series: Basic Science for the Cardiologist ((BASC,volume 16))

  • 147 Accesses

Abstract

Angiogenesis, or the formation of new blood vessels, is a complex, yet highly regulated process that is crucial for normal development and physiology, but when disturbed, contributes to the pathogenesis of at least 70 clinical disorders16,31,51. Millions of patients would therefore benefit from therapeutic modulation of blood vessel growth, if effective and specific stimulators and inhibitors could be identified. In spite of the fact that over 40 pro-angiogenic and anti-angiogenic compounds have been evaluated in clinical trials, none has yet been approved for general use.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Adini A, Kornaga T, Firoozbakht F, et al. Placental growth factor is a survival factor for tumor endothelial cells and macrophages. Cancer Res 62: 2749–52.

    Google Scholar 

  2. Aiello LP, Pierce EA, Foley ED, et al. 1995. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGFreceptor chimeric proteins. Proc Natl Acad Sci U S A 92: 10457–61.

    Article  PubMed  CAS  Google Scholar 

  3. Alon T, Hemo I, Itin A, et al. 1995. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1: 1024–8.

    Article  PubMed  CAS  Google Scholar 

  4. Arafat WO, Casado E, Wang M, et al. 2000. Genetically modified CD34+ cells exert a cytotoxic bystander effect on human endothelial and cancer cells. Clin Cancer Res 6: 4442–8.

    PubMed  CAS  Google Scholar 

  5. Asahara T, Takahashi T, Masuda H, et al. 1999. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. Embo J 18: 3964–72.

    Article  PubMed  CAS  Google Scholar 

  6. Assmus B, Schachinger V, Teupe C, et al. 2002. Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI). Circulation 106: 3009–17.

    Article  PubMed  Google Scholar 

  7. Autiero M, Waltenberger J, Communi D, et al. 2003. Role of PIGF in the intra-and intermolecular crosstalk between the VEGF receptors Flt1 and Flkl. Nat Med in press.

    Google Scholar 

  8. Bautz F, Rafii S, Kanz L, Mohle R. 2000. Expression and secretion of vascular endothelial growth factor-A by cytokine-stimulated hematopoietic progenitor cells. Possible role in the hematopoietic microenvironment. Exp Hematol 28: 700–6.

    Article  Google Scholar 

  9. Beck H, Acker T, Puschel AW, et al. 2002. Cell type-specific expression of neuropilins in an MCA-occlusion model in mice suggests a potential role in post-ischemic brain remodeling. J Neuropathol Exp Neurol 61: 339–50.

    PubMed  CAS  Google Scholar 

  10. Bottomley MJ, Webb NJ, Watson Ci, et al. 2000. Placenta growth factor (P1GF) induces vascular endothelial growth factor (VEGF) secretion from mononuclear cells and is co-expressed with VEGF in synovial fluid. Clin Exp Immunol 119: 182–8.

    Article  PubMed  CAS  Google Scholar 

  11. Breslow JL. 1996. Mouse models of atherosclerosis. Science 272: 685–8

    Article  PubMed  CAS  Google Scholar 

  12. Brown LF, Yeo KT, Berse B, et al. 1992. Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing. J Exp Med 176: 1375–9.

    Article  PubMed  CAS  Google Scholar 

  13. Bruner-Tran KL, Webster-Clair D, Osteen KG. 2002. Experimenta endometriosis: the nude mouse as a xenographic host. Ann N Y Acad Sci 955: 328–39; discussion 40–2, 96–406.

    Article  PubMed  Google Scholar 

  14. Buschmann I, Schaper W. 2000. The pathophysiology of the collateral circulation (arteriogenesis). J Pathol 190: 338–42.

    Article  PubMed  CAS  Google Scholar 

  15. Carmeliet P. 2000. Mechanisms of angiogenesis and arteriogenesis. Nat Med 6: 389–95.

    Article  PubMed  CAS  Google Scholar 

  16. Carmeliet P, Jain RK. 2000. Angiogenesis in cancer and other diseases. Nature 407: 249–57.

    Google Scholar 

  17. Carmeliet P, Luttun A. 2001. The emerging role of the bone marrow-derived stem cells in (therapeutic) angiogenesis. Thromb Haemost 86: 289–97.

    PubMed  CAS  Google Scholar 

  18. Carmeliet P, Moons L, Collen D. 1998. Mouse models of angiogenesis, arterial stenosis, atherosclerosis and hemostasis. Cardiovasc Res 39: 8–33.

    Article  PubMed  CAS  Google Scholar 

  19. Carmeliet P, Moons L, Luttun A, et al. 2001. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 7: 575–83.

    Article  PubMed  CAS  Google Scholar 

  20. Carmeliet P, Storkebaum E. 2002. Vascular and neuronal effects of VEGF in the nervous system: implications for neurological disorders. Semin Cell Dev Biol 13: 39–53.

    Article  PubMed  CAS  Google Scholar 

  21. Couffinhal T, Silver M, Zheng LP, et al. 1998. Mouse model of angiogenesis. Am J Pathol 152: 1667–79

    PubMed  CAS  Google Scholar 

  22. Courtenay JS, Dallman MJ, Dayan AD, et al. 1980. Immunisation against heterologous type II collagen induces arthritis in mice. Nature 283: 666–8.

    Article  PubMed  CAS  Google Scholar 

  23. Croll SD, Wiegand SJ. 2001. Vascular growth factors in cerebral ischemia. Mol Neurobiol 23: 121–35.

    Article  PubMed  CAS  Google Scholar 

  24. Dabrosin C, Gyorffy S, Margetts P, et al. 2002. Therapeutic effect of angiostatin gene transfer in a murine model of endometriosis. Am J Pathol 161: 909–18.

    Article  PubMed  CAS  Google Scholar 

  25. Deindl E, Buschmann I, Hoefer IE, et al. 2001. Role of ischemia and of hypoxia-inducible genes in arteriogenesis after femoral artery occlusion in the rabbit. Circ Res 89: 779–86

    Article  PubMed  CAS  Google Scholar 

  26. Detmar M, Brown LF, Claffey KP, et al. 1994. Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med 180: 1141–6.

    Article  PubMed  CAS  Google Scholar 

  27. Donnini S, Machein MR, Plate KFI, Weich HA. 1999. Expression and localization of placenta growth factor and P1GF receptors in human meningiomas. J Pathol 189: 66–71.

    Article  PubMed  CAS  Google Scholar 

  28. Epstein SE, Kornowski R, Fuchs S, et al. 2001. Angiogenesis therapy: amidst the hype, the neglected potential for serious side effects. Circulation 104: 115–9.

    Article  PubMed  CAS  Google Scholar 

  29. Failla CM, Odorisio T, Cianfarani F, Schietroma C, Puddu P, Zambruno G. 2000. Placenta growth factor is induced in human keratinocytes during wound healing. J Invest Dermatol 115: 388–95.

    Article  PubMed  CAS  Google Scholar 

  30. Ferrara N. 2001. Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am J Physiol (Cell Physiol) 280: C1358–66.

    Google Scholar 

  31. Folkman J. 2001. Angiogenesis-dependent diseases. Semin Oncol 28: 536–42.

    Article  PubMed  CAS  Google Scholar 

  32. Freedman SB, Isner JM. 2001. Therapeutic angiogenesis for ischemic cardiovascular disease. J Mol Cell Cardiol 33: 379–93.

    Article  PubMed  CAS  Google Scholar 

  33. Galli SJ, Hammel I. 1984. Unequivocal delayed hypersensitivity in mast cell-deficient and beige mice. Science 226: 710–3.

    Article  PubMed  CAS  Google Scholar 

  34. Malik AK, Solar GP, et al. 2002. VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature 417: 954–8

    Article  PubMed  CAS  Google Scholar 

  35. Hanahan D, Christofori G, Naik P, et al. 1996. Transgenic mouse models of tumour angiogenesis: the angiogenic switch, its molecular controls, and prospects for preclinical therapeutic models. Eur J Cancer 32A: 2386–93.

    Article  Google Scholar 

  36. Hata R, Mies G, Wiessner C, Fritze K, et al. 1998. A reproducible model of middle cerebral artery occlusion in mice: hemodynamic, biochemical, and magnetic resonance imaging. J Cereb Blood Flow Metab 18: 367–75.

    Article  PubMed  CAS  Google Scholar 

  37. Hattori K, Dias S, Heissig B, et al. 2001. Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells. J Exp Med 193: 1005–14.

    Article  PubMed  CAS  Google Scholar 

  38. Hattori K, Heissig B, Wu Y, Dias S, Tejada R, et al. 2002. Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bone-marrow microenvironment. Nat Med 8: 841–9.

    PubMed  CAS  Google Scholar 

  39. Hatva E, Bohling T, Jaaskelainen J, et al. 1996. Vascular growth factors and receptors in capillary hemangioblastomas and hemangiopericytomas. Am J Pathol 148: 763–75.

    PubMed  CAS  Google Scholar 

  40. Hayashi T, Abe K, Itoyama Y. 1998. Reduction of ischemic damage by application of vascular endothelial growth factor in rat brain after transient ischemia. J Cereb Blood Flow Metab 18: 887–95.

    Article  PubMed  CAS  Google Scholar 

  41. Heissig B, Hattori K, Dias S, et al. 2002. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell 109: 625–37

    Article  PubMed  CAS  Google Scholar 

  42. Hess DC, Hill WD, Martin-Studdard A, et al. 2002. Bone marrow as a source of endothelial cells and NeuN-expressing cells After stroke. Stroke 33: 1362–8

    Article  PubMed  Google Scholar 

  43. Heymans S, Luttun A, Nuyens D, et al. 1999. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med 5: 1135–42.

    Article  PubMed  CAS  Google Scholar 

  44. Hiratsuka S, Maru Y, Okada A, et al. 2001. Involvement of Flt-1 tyrosine kinase (vascular endothelial growth factor receptor-1) in pathological angiogenesis. Cancer Res 61: 1207–13.

    PubMed  CAS  Google Scholar 

  45. Hoshida T, Sunamura M, Duda DG, et al. 2002. Gene therapy for pancreatic cancer using an adenovirus vector encoding soluble flt- I vascular endothelial growth factor receptor. Pancreas 25: 111–21

    Article  PubMed  Google Scholar 

  46. Ikeda M, Hosoda Y, Hirose S, et al. 2000. Expression of vascular endothelial growth factor isoforms and their receptors Flt-1, KDR, and neuropilin-1 in synovial tissues of rheumatoid arthritis. J Pathol 191: 426–33.

    Article  PubMed  CAS  Google Scholar 

  47. Ikenaga S, Hamano K, Nishida M, et al. 2001. Autologous bone marrow implantation induced angiogenesis and improved deteriorated exercise capacity in a rat ischemic hindlimb model. J Surg Res 96: 277–83.

    Article  PubMed  CAS  Google Scholar 

  48. Isner JM. 2002. Myocardial gene therapy. Nature 415: 234–9.

    Article  PubMed  CAS  Google Scholar 

  49. Isner JM, Vale PR, Symes JF, et al. 2001. Assessment of risks associated with cardiovascular gene therapy in human subjects. Circ Res 89: 389–400.

    Article  PubMed  CAS  Google Scholar 

  50. Jacks T. 1996. Lessons from the p53 mutant mouse. J Cancer Res Clin Oncol 122: 319–27

    Article  PubMed  CAS  Google Scholar 

  51. Jain RK, Carmeliet PF. 2001. Vessels of death or life. Sci Am 285: 38–45.

    Google Scholar 

  52. Jin KL, Mao XO, Greenberg DA. 2000. Vascular endothelial growth factor: direct neuroprotective effect in in vitro ischemia. Proc Natl Acad Sci U S A 97: 10242–7.

    Article  PubMed  CAS  Google Scholar 

  53. Johnson R, Spiegelman B, Hanahan D, Wisdom R. 1996. Cellular transformation and malignancy induced by ras require c-jun. Mol Cell Biol 16: 4504–11.

    CAS  Google Scholar 

  54. Kalka C, Masuda H, Takahashi T, et al. 2000. Vascular endothelial growth factor(165) gene transfer augments circulating endothelial progenitor cells in human subjects. Circ Res 86: 1198–202.

    Article  PubMed  CAS  Google Scholar 

  55. Kawamoto A, Gwon HC, Iwaguro H, et al. 2001. Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia. Circulation 103: 634–7.

    Article  PubMed  CAS  Google Scholar 

  56. Kenyon BM, Voest EE, Chen CC, Flynn E, Folkman J, D’Amato RJ. 1996. A model of angiogenesis in the mouse cornea. Invest Ophthalmol Vis Sci 37: 1625–32.

    PubMed  CAS  Google Scholar 

  57. Kitagawa K, Matsumoto M, Yang G, et al. 1998. Cerebral ischemia after bilateral carotid artery occlusion and intraluminal suture occlusion in mice: evaluation of the patency of the posterior communicating artery. J Cereb Blood Flow Metab 18: 570–9.

    Article  PubMed  CAS  Google Scholar 

  58. Kocher AA, Schuster MD, Szabolcs MJ, et al. 2001. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med 7: 430–6.

    Article  PubMed  CAS  Google Scholar 

  59. Lee DM, Weinblatt ME. 2001. Rheumatoid arthritis. Lancet 358: 903–11.

    Article  PubMed  CAS  Google Scholar 

  60. Lu D, Jimenez X, Zhang H, et al. 2001. Complete inhibition of vascular endothelial growth factor (VEGF) activities with a bifunctional diabody directed against both VEGF kinase receptors, fms-like tyrosine kinase receptor and kinase insert domain-containing receptor. Cancer Res 61: 7002–8

    PubMed  CAS  Google Scholar 

  61. Lu J, Kasama T, Kobayashi K, et al. 2000. Vascular endothelial growth factor expression and regulation of murine collagen-induced arthritis. J Immunol 164: 5922–7.

    PubMed  CAS  Google Scholar 

  62. Luttun A, Carmeliet G, Carmeliet P. 2002. Vascular progenitors: from biology to treatment. Trends Cardiovasc Med 12: 88–96.

    Article  PubMed  CAS  Google Scholar 

  63. Luttun A, Tjwa M, Carmeliet P. 2002. Placental Growth Factor (PIGF) and Its Receptor Flt-1 (VEGFR-1): Novel Therapeutic Targets for Angiogenic Disorders. Ann N Y Acad Sci 979: 80–93

    Article  PubMed  CAS  Google Scholar 

  64. Luttun A, Tjwa M, Moons L, et al. 2002. Revascularization of ischemic tissues by P1GF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Fltl. Nat Med 8: 831–40.

    PubMed  CAS  Google Scholar 

  65. Lyden D, Hattori K, Dias S, et al. 2001. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 7: 1194–201.

    Article  PubMed  CAS  Google Scholar 

  66. Lyden D, Young AZ, Zagzag D, et al. 1999. Idl and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts. Nature 401: 670–7

    Article  PubMed  CAS  Google Scholar 

  67. Matsumoto Y, Tanaka K, Hirata G, et al. 2002. Possible involvement of the vascular endothelial growth factor-Flt-1-focal adhesion kinase pathway in chemotaxis and the cell proliferation of osteoclast precursor cells in arthritic joints. J Immunol 168: 5824–31

    PubMed  CAS  Google Scholar 

  68. McLeod DS, Taomoto M, Cao J, et al. 2002. Localization of VEGF receptor-2 (KDR/Flk1) and effects of blocking it in oxygen-induced retinopathy. Invest Ophthalmol Vis Sci 43: 474–82.

    PubMed  Google Scholar 

  69. Miotla J, Maciewicz R, Kendrew J, et al. 2000. Treatment with soluble VEGF receptor reduces disease severity in murine collagen-induced arthritis. Lab Invest 80: 1195–205. 70.Moulton KS. 2001. Plaque angiogenesis and atherosclerosis. Curr Atheroscler Rep 3: 225–33.

    Google Scholar 

  70. Niida S, Kaku M, Amano H, et al. 1999. Vascular endothelial growth factor can substitute for macrophage colony-stimulating factor in the support of osteoclastic bone resorption. J Exp Med 190: 293–8

    Article  PubMed  CAS  Google Scholar 

  71. Odorisio T, Schietroma C, Zaccaria ML, et al. 2002. Mice overexpressing placenta growth factor exhibit increased vascularization and vessel permeability. J Cell Sci 115: 2559–67.

    PubMed  CAS  Google Scholar 

  72. Oosthuyse B, Moons L, Storkebaum E, et al. 2001. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet 28: 131–8.

    Article  PubMed  CAS  Google Scholar 

  73. Oura H, Silva J, Velasco P, et al. 2003. A critical role of placental growth factor in the induction of inflammation and edema formation. Blood 15: 560–7

    Article  CAS  Google Scholar 

  74. Passaniti A, Taylor RM, Pili R, et al. 1992. A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Lab Invest 67: 519–28.

    PubMed  CAS  Google Scholar 

  75. Pettersson A, Nagy JA, Brown LF, et al. 2000. Heterogeneity of the angiogenic response induced in different normal adult tissues by vascular permeability factor/vascular endothelial growth factor. Lab Invest 80: 99–115.

    Article  PubMed  CAS  Google Scholar 

  76. Pierce EA, Avery RL, Foley ED, et al. 1995. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci U S A 92: 905–9.

    Article  PubMed  CAS  Google Scholar 

  77. Pipp F, Heil M, Issbrücker K, et al. 2003. VEGFR-1-selective VEGF homologue PIGF is arteriogenic. Evidence for a monocyte-mediated mechanism. Circ Res

    Google Scholar 

  78. Post MJ, Laham R, Sellke FW, et al. 2001. Therapeutic angiogenesis in cardiology using protein formulations. Cardiovasc Res 49: 522–31.

    Article  PubMed  CAS  Google Scholar 

  79. Rafii S, Meeus S, Dias S, et al. 2002. Contribution of marrow-derived progenitors to vascular and cardiac regeneration. Semin Cell Dev Biol 13: 61–7

    Article  PubMed  CAS  Google Scholar 

  80. Romano Di Peppe S, Mangoni A, Zambruno et al. 2002. Adenovirus-mediated VEGF(165) gene transfer enhances wound healing by promoting angiogenesis in CDI diabetic mice. Gene Ther 9: 1271–7.

    Article  PubMed  CAS  Google Scholar 

  81. Scappaticci FA. 2002. Mechanisms and future directions for angiogenesis-based cancer therapies. J Clin Oncol 20: 3906–27.

    Article  PubMed  CAS  Google Scholar 

  82. Schatteman GC, Hanlon HD, Jiao C, et al. 2000. Blood-derived angioblasts accelerate blood-flow restoration in diabetic mice. J Clin Invest 106: 571–8.

    Article  PubMed  CAS  Google Scholar 

  83. Schoch HJ, Fischer S, Marti HH. 2002. Hypoxia-induced vascular endothelial growth factor expression causes vascular leakage in the brain. Brain 125: 2549–57.

    Article  PubMed  Google Scholar 

  84. Scholz D, Ziegelhoeffer T, Helisch et al. 2002. Contribution of arteriogenesis and angiogenesis to postocclusive hindlimb perfusion in mice. J Mol Cell Cardiol 34: 775–87

    Article  PubMed  CAS  Google Scholar 

  85. Schratzberger P, Schratzberger G, Silver M, et al. 2000. Favorable effect of VEGF gene transfer on ischemic peripheral neuropathy. Nat Med 6: 405–13.

    Article  PubMed  CAS  Google Scholar 

  86. Sekimoto T, Hamada K, Oike Y, et al. 2002. Effect of direct angiogenesis inhibition in rheumatoid arthritis using a soluble vascular endothelial growth factor receptor 1 chimeric protein. J Rheumatol 29: 240–5

    PubMed  CAS  Google Scholar 

  87. Shibuya M. 2001. Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. Cell Struct Funct 26: 25–35

    Article  PubMed  CAS  Google Scholar 

  88. Simons M, Bonow RO, Chronos NA, et al. 2000. Clinical trials in coronary angiogenesis: issues, problems, consensus: An expert panel summary. Circulation 102: E73–86.

    Article  PubMed  CAS  Google Scholar 

  89. Smith LE, Wesolowski E, McLellan A, et al. 1994. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci 35: 101–11.

    PubMed  CAS  Google Scholar 

  90. Stefanik DF, Fellows WK, Rizkalla LR, et al. 2001. Monoclonal antibodies to vascular endothelial growth factor (VEGF) and the VEGF receptor, FLT-1, inhibit the growth of C6 glioma in a mouse xenograft. J Neurooncol 55: 91–100

    Article  PubMed  CAS  Google Scholar 

  91. Strauer BE, Brehm M, Zeus T, et al. 2002. Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation 106: 1913–8

    Article  PubMed  Google Scholar 

  92. Suzuki K, Murtuza B, Smolenski RT, et al. 2001. Cell transplantation for the treatment of acute myocardial infarction using vascular endothelial growth factor-expressing skeletal myoblasts. Circulation 104: I207–12.

    Article  PubMed  CAS  Google Scholar 

  93. Takahashi T, Kalka C, Masuda H, et al. 1999. Ischemia-and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med 5: 434–8.

    Article  PubMed  CAS  Google Scholar 

  94. Taylor RN, Lebovic DI, Mueller MD. 2002. Angiogenic factors in endometriosis. Ann N Y Acad Sci 955: 89–100; discussion 18, 396–406.

    Google Scholar 

  95. van Bruggen N, Thibodeaux H, Palmer JT, et al. 1999. VEGF antagonism reduces edema formation and tissue damage after ischemia/reperfusion injury in the mouse brain. J Clin Invest 104: 1613–20.

    Article  PubMed  Google Scholar 

  96. van Royen N, Piek JJ, Buschmann I, et al. 2001. Stimulation of arteriogenesis; a new concept for the treatment of arterial occlusive disease. Cardiovasc Res 49: 543–53.

    Article  PubMed  Google Scholar 

  97. Veikkola T, Karkkainen M, Claesson-Welsh L, et al. 2000. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res 60: 203–12.

    PubMed  CAS  Google Scholar 

  98. Ware JA. 2001. Too many vessels? Not enough? The wrong kind? The VEGF debate continues. Nat Med 7: 403–4.

    Article  PubMed  CAS  Google Scholar 

  99. Weber AJ, De Bandt M. 2000. Angiogenesis: general mechanisms and implications for rheumatoid arthritis. Joint Bone Spine 67: 366–83

    PubMed  CAS  Google Scholar 

  100. Weng DE, Usman N. 2001. Angiozyme: a novel angiogenesis inhibitor. Curr Oncol Rep 3: 141–6.

    Article  PubMed  CAS  Google Scholar 

  101. Zachary I. 2001. Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor. Am J Physiol Cell Physiol 280: C1375–86.

    PubMed  CAS  Google Scholar 

  102. Zhang Z, Chopp M. 2002. Vascular endothelial growth factor and angiopoietins in focal cerebral ischemia. Trends Cardiovasc Med 12: 62–6.

    Article  PubMed  CAS  Google Scholar 

  103. Zhu Z, Bohlen P, Witte L. 2002. Clinical development of angiogenesis inhibitors to vascular endothelial growth factor and its receptors as cancer therapeutics. Curr Cancer Drug Targets 2: 135–56

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, KU Leuven, Leuven, Belgium

    Lieve Moons, Aernout Luttun, Peter Carmeliet & Ed Conway

Authors
  1. Lieve Moons
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Aernout Luttun
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter Carmeliet
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ed Conway
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Physiology Academic Medical Center, University of Amsterdam, The Netherlands

    Can Ince

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer Science+Business Media New York

About this chapter

Cite this chapter

Moons, L., Luttun, A., Carmeliet, P., Conway, E. (2004). Mouse Models to Study Pro-and Antiangiogenic Potential: Novel Roles for PLGF and FLT1. In: Ince, C. (eds) The Physiological Genomics of the Critically Ill Mouse. Basic Science for the Cardiologist, vol 16. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-0483-2_23

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-0483-2_23

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-5099-6

  • Online ISBN: 978-1-4615-0483-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation